Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2017Medicinski casopisOpen Access

Direct oral anticoagulant drugs in the prophylaxis and therapy of thromboembolic diseases

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do direct oral anticoagulants prevent and treat thromboembolic events in patients at risk of or with thrombosis compared to conventional anticoagulants?

Population

Adult patients requiring prophylaxis or therapy for thromboembolic diseases, including non-valvular atrial…

Comparison

Direct oral anticoagulants and their specific… vs Conventional anticoagulants or placebo.

Design

Review

Authors

MTMilan TomićANAleksandra NovakovicPMPredrag Milojević

Discussion

Loading...

Member takes

Overview

Background on DOAC advantages over VKAs leaves open questions on real-world outcomes; prospective data needed before broader adoption.

Structured PICO

Do direct oral anticoagulants prevent and treat thromboembolic events in patients at risk of or with thrombosis compared to conventional anticoagulants?

P
Population
Adult patients requiring prophylaxis or therapy for thromboembolic diseases, including non-valvular atrial fibrillation, venous thromboembolism, acute coronary syndrome, and those undergoing elective hip or knee replacement surgery.
I
Intervention
Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) and their specific reversal agents (idarucizumab, andexanet alfa).
C
Comparator
Conventional anticoagulants (vitamin K antagonists such as warfarin, or low molecular weight heparins such as enoxaparin) or placebo.
O
Outcome
Efficacy in preventing and treating thromboembolic events (stroke, systemic embolism, deep vein thrombosis, pulmonary embolism) and safety (risk of major and clinically relevant bleeding).

Direct oral anticoagulants offer a convenient, safe, and effective alternative to vitamin K antagonists across multiple thromboembolic indications, supported by the development of specific reversal agents.

Cite This Study

Tomić et al. (2017) studied this question.

synapsesocial.com/papers/6a7219e36c240de38cdc4e62https://doi.org/10.5937/mckg51-15563
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors2009 · 26 citations
  2. 2Practical aspects of the oral new anticoagulants2011 · 28 citations
  3. 3Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity2010 · 1,381 citations
  4. 4Stroke Prevention in Atrial Fibrillation2017 · 18 citations
  5. 5Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)2011 · 402 citations